Cataract and the use of statins: A case-control study

QJM: An International Journal of Medicine

Volumn 96, Issue 5, 2003, Pages 337-343

  Smeeth, Liam ^a   Hubbard, R ^b   Fletcher, A E ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CERIVASTATIN; CLARITHROMYCIN; CORTICOSTEROID; CYCLOSPORIN; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; DILTIAZEM; ERYTHROMYCIN; ESTROGEN; FLUCONAZOLE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; MACROLIDE; NEFAZODONE; NICARDIPINE; PRAVASTATIN; PYRROLE DERIVATIVE; SIMVASTATIN; VERAPAMIL;

ADULT; AGED; ARTICLE; CATARACT; CLINICAL OBSERVATION; CONSULTATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG USE; FEMALE; GENERAL PRACTICE; GROUPS BY AGE; GROUPS BY SEX; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0037648948     PISSN: 14602725     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/hcg064     Document Type: Article

References (27)

1. World Health Organization Office of Information. Blindness and visual disability: part 2: major causes worldwide. WHO fact sheet no. 143. Geneva, WHO, 1997.
2. Dolin P. Epidemiology of cataract. In: Johnson GJ, Minassian DC, Weale R, eds. The epidemiology of eye disease. London, Chapman and Hall, 1998:103-18.
3. Gerson RJ, MacDonald JS, Alberts AW, Chen J, Yudkovitz JB, Greenspan MD, et al. On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors. Exp Eye Res 1990; 50:65-78.
4. Rao PV, Robison WG, Jr., Bettelheim F, Lin LR, Reddy VN, Zigler JS, Jr. Role of small GTP-binding proteins in lovastatin-induced cataracts. Invest Ophthalmol Vis Sci 1997; 38:2313-21.
5. Leclercq V, Harvengt C. Simvastatin (MK 733) in heterozygous familial hypercholesterolemia: a two-year trial. Int J Clin Pharmacol 1989; 27:76-81.
6. Schmidt J, Schmitt C, Hockwin O. No lens changes caused by simvastatin results from a prospective drug safety study. Lens Eye Toxic Res 1990; 7:643-50.
7. Lundh BL, Nilsson SE. Lens changes in matched normals and hyperlipidemic patients treated with simvastatin for 2 years. Acta Ophthalmol (Copenh) 1990; 68:658-60.
8. Boccuzzi SJ, Bocanegra TS, Walker JF, Shapiro DR, Keegan ME. Long-term safety and efficacy profile of simvastatin. Am.J Cardiol 1991; 68:1127-31.
9. Molgaard J, Lundh BL, von Schenck H, Olsson AG. Long-term efficacy and safety of simvastatin alone and in combination therapy in treatment of hypercholesterolaemia. Atherosclerosis 1991; 91:S21-8.
10. Schmidt J, Schmitt C, Hockwin O, Paulus U, von Bergmann K. Ocular drug safety and HMG-CoA-reductase inhibitors. Ophthalmic Res 1994; 26:352-60.
11. Harris ML, Bron AJ, Brown NA, Keech AC, Wallendszus KR, Armitage JM, et al. Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group. Br J Ophthalmol 1995; 79:996-1002.
12. Pedersen TR, Berg K, Cook TJ, Faergeman O, Haghfelt T, Kjekshus J, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1996; 156:2085-92.
13. Qian W, Soderberg PG, Chen E, Magnius K, Philipson B. 3 year simvastatin treatment and lens nuclear back scattering. Br J Ophthalmol 2000; 84:512-16.
14. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals a randomised placebo-controlled trial. Lancet 2002; 360:7-22.
15. Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002; 360:2-3.
16. Lawson DH, Sherman V, Hollowell J. The General Practice Research Database. Scientific and Ethical Advisory Group. Q J Med 1998; 91:445-52.
17. Office for National Statistics. Key health Statistics from general practice 1996 (Series MB6 No. 1). London, Office for National Statistics, 1998.
18. Walley T, Mantgani A. The UK General Practice Research Database. Lancet 1997; 350:1097-9.
19. Ruigomez A, Garcia Rodriguez LA, Dev VJ, Arellano F, Raniwala J. Are schizophrenia or antipsychotic drugs a risk factor for cataracts? Epidemiology 2000; 11:620-3.
20. Stata 7.0. Texas, Stata Corporation, 2001.
21. Bottorff M, Hansten P. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism-monograph for physicians. Arch Intern Med 2000; 160:2273-80.
22. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002; 41:343-70.
23. Paoletti R, Corsini A, Bellosta S. Pharmacological interactions of statins. Atheroscler Suppl 2002; 3:35-40.
24. Christen WG, Glynn RJ, Ajani UA, Schaumberg DA, Buring JE, Hennekens CH, et al. Smoking cessation and risk of age-related cataract in men. JAMA 2000; 284:713-16.
25. Office for National Statistics. Living in Britain: Preliminary Results from the 1996 General Household Survey. London, The Stationery Office, 1997.
26. Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med 2000; 161:5-8.
27. Schlienger RG, Haefeli WE, Jick H, Meier CR. Risk of cataract in patients treated with statins. Arch Intern Med 2001; 161:2021-6.